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ABSTRACT 
Background: Renal cell carcinoma patients respond poorly to conventional 
chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). 
The mechanisms of MDR in renal cancer are not fully understood and the specific 
contribution of ABC transporter proteins which have been implicated in the 
chemoresistance of various cancers has not been fully defined in this disease.  
Methods: In this retrospective study the expression of two of these transporter efflux 
pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by 
immunohistochemistry in archival material from 95 renal cell carcinoma patients.  
Results:  In the first study investigating MDR-1 P-gp and MRP-1 protein expression 
patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps 
are observed with 100% of tumours studied showing MDR-1 P-gp and MRP-1 positivity.     
Conclusion: Although these findings do not prove a causal role, the high frequency of 
tumours expressing these efflux pumps suggests that they may be important contributors 
to the chemoresistance of this tumour type.  
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Background 
Kidney cancer accounts for approximately 2% of all adult cancers. It is the 7th leading 
cause of cancer in the US with an estimated incidence of approximately 51,000 new 
cancer cases per year in 2007 [1]. Renal cell carcinoma (RCC) is the most common 
tumour arising from the cells in the lining of tubules in the kidney [2]. At the time of 
diagnosis, 30% of patients will have metastatic or unresectable disease, and the 2-year 
overall survival of this cohort is <10% [3]. The incidence of kidney cancer is rising; it is 2 
times more common in men than women. Risk factors include obesity [4], smoking [5] 
and hypertension [6]. 
RCC is a chemoresistant tumour usually exhibiting only a marginal response. 
Radiotherapy and chemotherapy are generally ineffective in the treatment of advanced 
renal tumours [7, 8]. The intrinsic occurrence of multidrug resistance (MDR) modulates 
the resistance of tumours to a wide variety of and structurally distinct chemotherapeutic 
drugs through the expression of drug efflux pumps [9]. Two of the most widely studied 
efflux pumps, MDR-1 P-gp/ P-170, the gene product of MDR-1 (ABCB1) and MRP-1 
(ABCC1) which encodes a 190 kDa membrane protein have both been demonstrated to 
pump a wide variety of the most commonly used cancer drugs out of tumour cells. Their 
over expression correlates broadly with drug resistance in many different forms of cancer 
including pancreatic cancer [10], lung cancer [11], breast cancer [12] and glioma [13]. The 
relative contributions and causative role, if any, of MDR associated protein efflux pumps 
in renal carcinoma have not been fully elucidated. 
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Studies detailing the prevalence and contribution of MDR-1 P-gp in RCC are conflicting.  
MDR-1 P-gp expression has been reported widely in untreated renal carcinomas [14, 15]. 
It does appear that intrinsic drug resistance exists in many renal RCC and it is associated, 
at least in part, with increased expression of MDR-1 P-gp. However, the exact prognostic 
significance of this expression remains unclear with conflicting results described. Longer  
progression free survival has been observed in patients with none or very few MDR-1 P-
gp positive tumour cells compared to patients with a larger proportion of MDR-1 Pgp 
positive tumour cells [16, 17]; however higher MDR-1 expression has been associated 
with a better outcome also  [18, 19]. Expression of MDR-1 P-gp has been shown to 
correlate with a well differentiated tumour phenotype in renal carcinoma [18, 20, 21]. 
Higher MDR-1 gene expression has been observed in RCCs that have metastasised/ 
invaded through the renal capsule compared to early stage non invasive tumours [20, 22]. 
Studies addressing the contribution, if any, of the MRP-1 efflux pump and its gene 
product in this disease are limited. MRP-1, like MDR-1 P-gp is highly expressed in 
normal kidney. MRP-1 gene over expression has been observed in renal carcinomas, this 
expression does not appear to correlate with grade/clinical stage in this disease [19, 23]. 
To our knowledge, there have been no reported studies looking at MRP-1 protein 
expression in RCC.  
In this study, we evaluate the expression of MDR efflux pumps, MDR-1 P-gp and MRP-1, 
using immunhistochemical analysis, in 95 RCCs, to investigate the relative contributions 
of these efflux pumps in this disease.  
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Methods                                                                                                                             
Patients 
The patient group consisted of 95 consenting patients diagnosed with primary renal cell 
carcinomas. All patients were treated at St. Vincent’s University Hospital (SVUH), Dublin 
between 1999 and 2003. Approval to conduct this study was granted by the SVUH Ethics 
Committee. Pathological material was examined on each case by SK. Formalin-fixed 
paraffin-embedded material was available for all patients. Representative 4-µm sections of 
tissue blocks were cut using a microtome, mounted onto poly-l-lysine coated slides and 
dried overnight at 37 oC. Slides were stored at room temperature until required. 
Clinicopathological features, where available were compiled for relevant patients. 
Immunohistochemistry 
Immunohistochemical studies were performed on formalin fixed paraffin embedded renal 
carcinomas as described previously [12]; using anti-MDR-1 P-gp (antibody MDR-1, 6/1C; 
National Institute for Cellular Biotechnology [24]: ascites diluted 1:40) and anti-MRP-1 
(antibody PA28(6), neat supernatant, National Institute for Cellular Biotechnology [25]). 
Positive control tissues (normal kidney and lung tissue) and negative control specimens in 
which primary antibody was replaced by 1XTBS/0.05% Tween 20 were included in all 
experiments. 
Immunohistochemical scoring 
MDR-1 P-gp and MRP-1 immunohistochemical staining was evaluated semi-
quantitatively, according to the percentage of cells showing specific immunoreactivity and 
the intensity of this immunoreactivity. Scoring involved evaluation of at least 5 fields of 
view per slide, by two independent observers. In the case of both MDR-1 P-gp and MRP-
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1, membrane and cytoplasmic staining was scored as positive or negative. A semi-
quantitative measurement was used in which overall positivity of the tumour was assessed 
and a score of 1+ was given where up to 25% of cells showed MDR-1 P-gp/ MRP-1 
positive staining; a score of 2+ was given where ≥ 25% but < 50% of cells showed MDR-
1 P-gp/MRP-1 positive staining; a score of 3+, where ≥ 50% but <75% of cells showed 
positive staining and a score of 4+, where ≥ 75% of cells showed positive staining. For 
assessment of both MDR-1/P-gp and MRP-1 protein, the intensity of immunoreactivity 
was scored as 1 (weak), 2 (moderate), or 3 (strong) as outlined in table 1. 
 
Results  
MDR-1/P-gp expression                                          
The immunohistochemical analysis revealed that of the 95 cases, MDR-1 P-gp specific 
staining was observed weakly positive in 22% (21/95), moderate staining was observed in 
40% (38/95) and strong staining in 38% (36/95) of RCCs analysed. Figure 1 (A) shows a 
representative MDR-1 P-gp positive tumour where intense MDR-1 P-gp positivity is 
observed (score of 4+3) and (B) MDR-1 P-gp positive tumour with moderate staining 
intensity (score of 2+2). Specific staining was localised to the cell membrane and 
cytoplasm. The majority of tumours had between 50-75% positive staining for MDR-1 P-
gp, associated with an intermediate (+2) intensity positive staining (3+2). 76% of tumours 
(72/95) showed MDR-1 P-gp staining in 50% or more of tumour cells. As outlined in 
Table 2, the distribution of MDR-1 P-gp expression was analysed by percentage staining, 
age, gender, tumour size, tumour grade and nodal status (if known). Of the 95 MDR-1 Pgp 
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positive RCC, 6% (6/95) scored 1, 18% (17/95) scored 2, 45% (43/95) scored 3 and 31% 
(29/95) scored 4 percentage staining of MDR-1 Pg-p.  
 
MRP-1 expression   
All 95 RCC showed MRP-1 protein expression; MRP-1 specific staining was observed 
weakly positive in 21% (20/95), moderate staining was observed in 49% (47/95) and 
strong staining observed in 29% (27/95) of RCC analysed. Figure 1 (C) illustrates an 
MRP-1 strongly positive (score of 4+3) tumour and (D) an MRP-1 positive tumour 
showing less intense MRP-1 staining (score of 2+2). Table 3 shows a breakdown of the 
distribution of MRP-1 positive tumours. Of the cases expressing MRP-1, 7% (7/95) scored 
1, 32% (30/113) scored 2, 40% (38/95) scored 3 and 21% (20/95) scored 4. 61% of 
tumours (58/95) showed MRP-1 staining in 50% or more of tumour cells.  
The highest percentage staining and intensity of MRP-1 expression was observed in male 
patients over the age of 60 with grade 2 tumours of < 7 cm in size and with positive nodal 
status. 
 
Correlation between MDR-1 P-gp and MRP-1 
All tumours studied expressed both MDR-1 P-gp and MRP-1; intensity levels of these 
transporters did not vary to any great degree, however a higher proportion (76%) of MDR-
1 positive tumours exhibited positive staining in 50% or more of tumour cells compared to 
MRP-1 staining patterns where 61% of MRP-1 positive tumours exhibited staining in 50% 
or more of tumour cells.  
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Discussion                                                                                                                
Chemotherapy is the standard treatment for most solid tumours; however, RCC is 
generally resistant to chemotherapy. The reason for the resistance of kidney cancer cells to 
chemotherapy is not completely understood. The specific role and relative contributions of 
ABC transporter pumps in clinical resistance in RCC have not been fully determined; 
results from previous studies are conflicting.   
The MDR1 gene and its gene product, P-gp are ubiquitously expressed in mesangial, 
proximal tubule, thick loop of Henle, and collecting duct cells of the kidney [26]. As P-gp 
plays a functional role in the clearance of xenobiotics from the mesangial and proximal 
tubule cells of the kidney, this may contribute to the inherent multidrug resistance 
phenotype of RCC. MDR-1 gene overexpression or protein have been identified in the 
majority of RCC samples studied [14-17, 19, 21].  
In this reterospective study we have shown that renal cancer cells produce an 
overabundance of this drug efflux pump, with 100% of RCCs studied exhibiting MDR-1 
P-gp positivity. 76% of these tumours exhibited MDR-1 P-gp staining in 50% or more of 
tumour cells. As renal tissue inherently expresses high levels of this transporter; results 
presented here are not unexpected. Using a similar scoring system as that used here, 
Mignogna et al., [16] observed MDR-1 P-gp expression in 100% (30/30) of RCC. Other 
immunohistochemical studies on smaller patient cohorts report 61.5% (8/13) and 47.6% 
(10/21) of RCC showing MDR-1 P-gp positivity [14, 15]; studies investigating MDR-1 
gene expression in RCC report varying levels of gene expression, in general slightly less 
that the MDR-1 P-gp protein expression observed here [19, 20-23]. It is well recognised 
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that protein levels do not necessarily correlate with mRNA levels, furthermore these 
differences between the various studies may in part result from the different techniques 
employed and different cohorts of patients and scoring criteria used. The high levels of 
MDR-1 P-gp expression observed here do suggest that this transporter protein is 
contributing, at least in part, to the chemoresistance of RCCs studied here. 
Mignogna et al., [16] suggested a role for MDR-1 P-gp as a possible adverse prognostic 
factor of chemoresistance and aggressive behaviour in renal carcinoma, their study 
showed an association between high MDR-1 P-gp expression (MDR-1 positivity in 40% 
or more of tumour cells) and poor survival as confirmed by Cox multivariate analysis. In 
agreement with this study, Duensing et al., [17] suggested a potential role for P-gp as a 
biologic parameter predictive of tumour progression in renal cell carcinoma patients, as 
longer disease-free survival was observed in patients with <1% MDR-1 positivity. 
However, Hofmockel et al., [18] correlated lower MDR-1 expression with poorer 
prognosis. Due to the lack of data regarding patient outcome; any possible prognostic 
significance of the expression of these efflux pumps observed could not be addressed in 
this study.  
Expression of this efflux pump does not appear to be associated with the histological 
tumour grade of RCC in this patient cohort. Unexpectedly lower MDR-1 levels have been 
shown to be associated with poorly differentiated RCC [18, 20-22]. However, in 
agreement with our observations Mignogna et al., showed MDR-1 protein expression as 
having prognostic significance independent of any association with tumour grade [16]. 
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We have also shown high levels of MRP-1 protein expression in RCC; all tumours 
investigated showed MRP-1 protein expression with 61% of tumours exhibiting MRP-1 
positivity in at least 50% of tumour cells. As in the case of MDR-1 Pgp, this efflux pump 
is also expressed at high levels in the normal kidney; so such an observed high level of 
expression again is not unexpected. This is the first report to our knowledge of MRP-1 
protein expression being investigated in RCC patients, previous work has focused on gene 
expression studies. Again, this observed high level of MRP-1 protein expression suggests 
that this efflux pump also may be playing a contributing role in the chemoresistance of 
these renal carcinomas. 
There was no apparent correlation between expression of either of the MDR proteins 
studied here with other clinicopathological features (gender, tumour size and nodal status). 
It was unfeasible to carry out detailed statistical analysis due to limitations and inadequate 
data. Histological grade, pathological stage and tumour size have been demonstrated using 
multivariate analysis to be significant prognostic indicators regarding RCC patient 
outcome [27]. Recently described molecular and genetic markers may also provide 
diagnostic and prognostic value in RCC [28]. 
It is likely that chemoresistance in RCC is multifactorial, other factors implicated as being 
involved in the complex chemoresistance mechanisms of RCC include Clusterin [29]; 
there also is some evidence that lung resistance protein (LRP/MVP) may contribute to 
inherently resistant renal carcinoma [30, 31].  
 The inherent resistance of RCC to conventional treatment has lead to the use of 
immunotherapies such as alpha-interferon and interleukin-2 (IL-2). However, response 
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does not translate to long-term benefit and does not prolong overall survival in many cases 
[32-34]. Newer “targeted-therapies” such as sunitinib [34, 35] are emerging for the 
treatment of patients resistant/intolerant to current treatment modalities or as an alternative 
to cytokine immunotherapy. Identification of new tumour associated antigens may 
hopefully provide the basis of new therapeutic strategies and lead to an improved outcome 
for this aggressive and chemoresistant disease. 
Conclusion 
Both MDR-1 P-gp and MRP-1 were expressed in 100% of the 95 specimens analysed. 
These high levels of expression suggest that both of these efflux pumps may be important 
contributors to the MDR phenotype in RCC. The incidence of MRP-1 positive tumours 
observed here warrants further study in order to confirm a possible contribution to 
chemoresistance in renal carcinoma. Due to the lack of data on the direct outcome of 
patients in this study, the prognostic significance of observed MDR protein expression 
was outside the scope of this investigation. Extensive studies with complete follow-up 
detailing expression of MDR-1 P-gp and MRP-1 together with further MDR associated 
markers (including LRP and MRP family members) and associated proteins may help to 
fully elucidate the specific contributions of these efflux pumps to the chemoresistance of 
RCC and furthermore address any possible prognostic and/ or predictive role.  
 
 
 
 12
Authors Contributions 
LOD, MC & JC conceived of and designed the study. NW performed 
immunohistochemical studies and analysis and interpretation of results. AML contributed 
to design, interpretation of results and supervised the research. LOD 
organised and compiled data base of clinicopathological information. SK provided clinical 
material and scored slides. LC contributed to design of immunohistochemical studies. JB, 
WO & GG acquired clinico-pathological information. NW and AML drafted manuscript 
and revised it critically for important intellectual content. All authors read and approved 
the final manuscript. 
Acknowledgements 
This work was supported by funding from Ireland’s Higher Educational Authority 
Programme for Research in Third Level Institutions (PRTLI) Cycle 3, Dublin City 
University’s Faculty of Science and Health Targeted Research Initiative, and Dublin City 
University’s Research Fellowship. 
 
Abbreviations: 
IL-2, interleukin-2; LRP, Lung resistance protein; MVB, major vault protein; MDR, 
Multiple Drug Resistance; MRP-1, Multiple Drug Resistance associated protein 1; MDR-
1, Multiple Drug Resistance protein 1; RCC, renal cell carcinoma; SVUH; St. Vincents 
University Hospital; TBS, Tris buffered saline. 
 
Competing Interests: 
The authors declare that they have no competing interests. 
 13
References 
[1] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA 
Cancer J Clin 2007, 57:43-66.  
[2] Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 1998, 352:1691-1696.  
[3] Reeves DJ, Liu CY: Treatment of metastatic renal cell carcinoma. Cancer 
Chemother Pharmacol. Epub 2009, 64:11-25. 
[4] Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and 
proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.  
[5] Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE: Risk factors for 
renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007, 166:932-940.  
[6] Chow WH, Gridley G, Fraumeni JF,Jr, Jarvholm B: Obesity, hypertension, and the 
risk of kidney cancer in men. N Engl J Med 2000, 343:1305-1311.  
[7] De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J: Gemcitabine: a phase II 
study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996, 
37:491-495.  
[8] Chan DY, Marshall FF: Surgery in advanced and metastatic renal cell carcinoma. 
Curr Opin Urol 1998, 8:369-373.  
[9] O'Connor R. The pharmacology of cancer resistance. Anticancer Res 2007, 
27:1267-1272.  
[10] O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, 
Crown J, Kennedy S: MDR1/P-glycoprotein and MRP-1 drug efflux pumps in 
pancreatic carcinoma. Anticancer Res 2007, 27:2115-2120.  
 14
[11] Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, Perez De Villarreal M, Crown J, 
O'Driscoll L: MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in 
non-small cell lung cancer. Anticancer Res 2007, 27:1325-1330.  
[12] Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, 
Clynes M: Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in 
invasive breast cancer: a prognostic study. Int J Cancer 2004, 112:286-294.  
[13] Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani 
A, Vitellaro-Zuccarello L, Croci D et al.: Expression of drug resistance proteins Pgp, 
MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005, 74:113-121.  
[14] Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J: Expression of 
P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993, 
24:156-160.  
[15] Bak M,Jr, Efferth T, Mickisch G, Mattern J, Volm M: Detection of drug resistance 
and P-glycoprotein in human renal cell carcinomas. Eur Urol 1990, 17:72-75.  
[16] Mignogna C, Staibano S, Altieri V, De Rosa G, Pannone G, Santoro A, Zamparese R, 
D'Armiento M, Rocchetti R, Mezza E et al.: Prognostic significance of multidrug-
resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up 
analysis. BMC Cancer 2006, 6:293.  
[17] Duensing S, Dallmann I, Grosse J, Buer J, Lopez Hanninen E, Deckert M, Storkel S, 
Kirchner H, Poliwoda H, Atzpodien J: Immunocytochemical detection of P-
glycoprotein: initial expression correlates with survival in renal cell carcinoma 
patients. Oncology 1994, 51:309-313.  
 15
[18] Hofmockel G, Bassukas ID, Wittmann A, Dammrich J: Is the expression of 
multidrug resistance gene product a prognostic indicator for the clinical outcome of 
patients with renal cancer? Br J Urol 1997, 80:11-17. 
[19] Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, 
Fourme E, Chevillard S: Expression of genes involved in chemoresistance, 
proliferation and apoptosis in clinical samples of renal cell carcinoma and 
correlation with clinical outcome. Anticancer Res 2002, 22:121-128.  
 [20] Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM: MDR1 
RNA levels in human renal cell carcinomas: correlation with grade and prediction of 
reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 
1989, 81:844-849.  
[21] Rochlitz CF, Lobeck H, Peter S, Reuter J, Mohr B, de Kant E, Huhn D, Herrmann R: 
Multiple drug resistance gene expression in human renal cell cancer is associated 
with the histologic subtype. Cancer 1992, 69:2993-2998.  
 [22] Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick RW, Skorecki KL, Warner E: 
Expression of the multiple drug resistance gene in human renal cell carcinoma 
depends on tumor histology, grade, and stage. Clin Cancer Res 1995, 1:1611-1615.  
[23] Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O: Expression 
patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein 
(MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) 
genes in renal cell carcinomas and normal kidney. J Urol 1996, 156:506-511. 
 16
 [24] Moran E, Larkin A, Doherty G, Kelehan P, Kennedy S, Clynes M: A new mdr-1 
encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded 
tissue without pretreatment of sections. J Clin Pathol 1997, 50:465-471.  
[25] Connolly L, Moran E, Larkin A, Scheffer G, Scheper R, Sarkadi B, Kool M, Clynes 
M: A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope 
on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor 
MRP3. Hybrid Hybridomics 2001, 20:333-341.  
[26] Ernest S, Bello-Reuss E: P-glycoprotein functions and substrates: possible roles of 
MDR1 gene in the kidney. Kidney Int Suppl 1998, 65:S11-7. 
 [27] Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Mejean A, Valeri A, Ficarra V, 
Pfister C, Ferriere JM, Soulie M et al.: Prognostic variables to predict cancer-related 
death in incidental renal tumours. BJU Int 2008, 102:1376.          
[28] Filosa A, Fabiani A. Renal cell carcinoma : molecular and genetic markers as 
new prognostic and therapeutic tools. Anal Quant Cytol Histol 2008, 30:341-343. 
[29] Hara I, Miyake H, Gleave ME, Kamidono S: Introduction of clusterin gene into 
human renal cell carcinoma cells enhances their resistance to cytotoxic 
chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer 
Res 2001, 92:1220-1224.  
 [30] Kong CZ, Zeng Y, Wu XX, Li JQ, Zhu YY, Chen Y: Increased expression of lung 
resistance-related protein in lower grade urothelial carcinoma of the renal pelvis and 
ureter. Int J Urol 2004, 11:721-727.  
[31] Ferguson RE, Jackson SM, Stanley AJ, Joyce AD, Harnden P, Morrison EE, Patel 
PM, Phillips RM, Selby PJ, Banks RE: Intrinsic chemotherapy resistance to the 
 17
tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 2005, 
115:155-163.  
[32] Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, 
Rintala E, Hietanen P, Kellokumpu-Lehtinen PL: Prospective randomized trial of 
interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced 
renal cell cancer. J Clin Oncol 1999, 17:2859-2867. 
[33] Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, 
Seipp CA, Rogers-Freezer L, Morton KE, White DE et al.: Randomized study of high-
dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 
2003, 21:3127-3132. 
[34] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, 
Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-Del-Muro X, Sosman JA, Solska E, 
Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA : Overall Survival and 
Updated Results for Sunitinib Compared With Interferon Alfa in patients with 
Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009 Jun 1 (Epub ahead of print) 
 [35] Kontovinis LF, Papazisis LK, Touplikioti P N, Andreadis C, Mouratidou D, Kortsari 
AH : Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: 
clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9:82. 
 
 
 
 
 
 18
Table 1: Percentage and intensity grade of staining. 
PPercentage grade of staining staining Intensity grade of staining grade of 
staining 
1=   1<25% Level 1 =   weak staining 
2=   ≥25-50% Level 2 =   moderate staining 
3=   ≥50<75% Level 3 =   strong staining 
4=   ≥75<100%  
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Table 2: P-gp expression in renal cell carcinoma and association with age at 
diagnosis, tumour size and histological grade and nodal status (n=95) 
 Number Strong (+3) Moderate  (+2) Weak  (+1) 
Cases expressing P-gp 95    
Percentage Staining     
1+            (1< 25%) 6 0 2 4 
2+            (≥ 25-50%) 17 5 8 4 
3+            (≥ 50< 75%) 43 9 23 11 
4+            (≥ 75%) 29 22 5 2 
Age     
< 60 41 20 13 8 
> 60 54 16 25 13 
Gender     
Male 49 26 17 6 
Female 46 10 21 15 
Tumour size                      
< 7 cm 56 21 26 9 
> 7 cm 39 15 12 12 
Tumour grade 
(7 unknown) 
    
Grade 1  16 5 8 3 
Grade 2  35 16 15 4 
Grade 3  37 13 13 11 
Nodal status 
(56 unknown) 
    
Positive 31 10 15 6 
Negative 8 2 4 2 
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Table 3: MRP-1 expression in renal cell carcinoma and association with age at 
diagnosis, tumour size and histological grade and nodal status (n=95) 
 Number Strong (+3) Moderate (+2) Weak  (+1) 
Cases expressing MRP-1 95    
Percentage Staining     
1+            (1< 25%) 7 0 2 5 
2+            (≥ 25-50%) 30 2 16 12 
3+            (≥ 50< 75%) 38 13 23 2 
4+            (≥ 75%) 20 13 6 1 
Age     
< 60 41 14 19 8 
> 60 54 14 28 12 
Gender     
Male 49 15 25 9 
Female 46 13 22 11 
Tumour size                      
< 7 cm 56 14 29 13 
> 7 cm 39 14 17 7 
Tumour grade 
(7 unknown) 
    
Grade 1  16 5 7 4 
Grade 2  35 8 19 8 
Grade 3   37 14 17 6 
Nodal status 
(56 unknown) 
    
Positive 31 8 17 6 
Negative 8 2 3 3 
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Figure legends 
Figure 1. Immunohistochemical analysis of MDR-1 P-gp and MRP-1 protein expression 
in RCC (A) RCC tumour showing positive MDR-1 P-gp staining with strong MDR-1 
positivity observed, score (4+3) (scale bar = 100μm) and (B) MDR-1 P-gp positive RCC  
with moderate positivity observed, score (2+2) (scale bar = 100μm) (C) MRP-1 positive 
tumour showing intense MRP-1 positive staining, score (4+3) (scale bar = 100μm) and 
(D) MRP-1 positive RCC with moderate  positivity observed, score (2+2) (scale bar = 
100μm). (Original magnifications of all photomicrographs X40). 
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